This study aimed to assess the efficacy and safety of our newly developed nasal glucagon-like peptide-1 (GLP-1) compound and injector.
The drug was an intranasal powder formulation (Asubio Pharma, Kobe, Japan) and supplied as a capsule containing 1.2 mg of recombinant human GLP-1 (7-36) amide prepared by coating the core particle with corn starch attached to the surface of calcium carbonate with a mean particle diameter of ;60 mm. GLP-1 and its formulation were produced in compliance with Good Manufacturing Practice-grade 
Patients
Outpatients aged 20-70 years with inadequately controlled type 2 diabetes using a stable regimen of oral antidiabetic drugs were recruited. Patients with severe micro-and macrovascular complications, frequent hypoglycemic episodes, abnormalities of the nasal cavity, severe liver and renal dysfunction, or bronchial asthma were excluded.
Study Design
This trial (UMIN-CTR ID 3123) was conducted as a prospective, randomized, double-blind, placebo-controlled study. This study was approved by the Ethics Committee of Miyazaki University, and all subjects provided written informed consent.
Participants were randomly assigned to the GLP-1 or placebo group in 2:1 ratio using a computer-generated random number sequence. A single intranasal application of the drug was performed to evaluate the pharmacokinetics and pharmacodynamics after an overnight fast. The drugs were administered just before a test meal of 578 kcal (carbohydrate, 52%; fat, 35%; protein, 13%). Blood sampling was performed just before intranasal administration and 5, 15, 30, 45, 60, 90, 120, and 180 min after administration. The 2-week intranasal administration was performed immediately before each meal. Regimens of oral hypoglycemic agents were unchanged during this trial. Blood sampling, medical examination, and measurement of hunger sensation using a 100-mm visual analog scale before each meal were performed on days 0, 7, and 14.
Bioanalytical Methods
Plasma glucagon levels were measured by radioimmunoassay (SRL, Tokyo, Japan). Plasma active GLP-1 levels were measured using blood sampling tubes containing dipeptidyl peptidase-4 inhibitors and an ELISA kit (Millipore, Billerica, MA) after ethanol extraction of plasma samples (8) .
Statistical Methods
Data are presented as mean 6 SD. Variables at single time points or area under the curve (AUC) were compared by paired or unpaired t tests. Two-way ANOVA for repeated measures with post hoc analysis to analyze time-course curves was also performed. A P value ,0.05 was considered statistically significant.
RESULTS
Eighteen and eight patients were entered into the GLP-1 and placebo groups, respectively. Age (60.5 6 5.4 vs. 61.1 6 8.1 years; P = 0.74), sex (male; 8 vs. 5; P = 0.39), BMI (27.4 6 5.2 vs. 24.0 6 1.8; P = 0.09), HbA 1c levels (7.7 6 0.6 vs. 7.5 6 0.6%; P = 0.74), or use of oral antidiabetic agents did not differ significantly between groups. Plasma active GLP-1 levels increased to 47.2 pmol/L 5 min after the intranasal administration of GLP-1 and then gradually decreased (Fig. 1A) . Tmax of plasma active GLP-1 was 8.1 min. Bioavailability of intranasal GLP-1 was 2.7% compared with intravenous administration (9). Plasma active GLP-1 levels 5-30 min after administration (Fig. 1A) and AUC at 180 min (data not shown) were significantly higher in the GLP-1 group than in the placebo group. Serum insulin levels in the GLP-1 group tended to be higher than in the placebo group at 5 min (P = 0.069) and were significantly higher at 15 min (Fig. 1B) . Plasma glucose levels tended to be lower in the GLP-1 group, but differences, including AUC, were not significant (Fig. 1C) . The increase in plasma glucose levels from baseline to 30 min in the GLP-1 group was significantly lower than that in the placebo group (Fig.  1D) . Increases in plasma glucagon levels from baseline to 30 and 180 min in the GLP-1 group were significantly lower than those in the placebo group, although plasma glucagon levels did not differ between groups (Fig. 1E and F) .
During this trial, 98.8% of the drugs were administered as planned. At day 14, glycoalbumin levels significantly decreased compared with day 0 only in the GLP-1 group (19.4 6 3.3 to 18.8 6 3.1%; P = 0.003) and were significantly lower in the GLP-1 group than in the placebo group (19.3 6 2.5%; P = 0.034). The 1,5-anhydroglucitol levels significantly increased at day 14 compared with day 0 only in the GLP-1 group (8.0 6 6.9 to 8.7 6 6.5 mg/mL; P = 0.036) and were significantly higher in the GLP-1 group than in the placebo group (7.9 6 5.1 mg/mL; P = 0.041). Body weight, total food intake, and hunger sensation measured using the visual analog scale before each meal did not differ between groups during the trial.
No marked adverse events including vomiting were observed after intranasal GLP-1. Nausea and discomfort occurred in three and two patients, respectively, receiving intranasal GLP-1, but were transient and disappeared within 3 days. Hypoglycemic symptoms occurred in three patients only in the placebo group who were taking sulphonylureas. No patients withdrew during the study. Intranasally administered GLP-1 can be absorbed rapidly from the nasal submucosa via many capillary vessels (4) . Some portions of intranasally administered GLP-1 may enter the cerebrospinal fluid and directly affect the feedingregulatory centers in the brain, as is the case with intranasally administered insulin (10,11). Although patients' body weights in this short-term study did not change, anorexigenic effects of GLP-1 should be determined in the next long-term trial. The need for subcutaneous injection is a major reason that patients refuse to use GLP-1 analog drugs (2). Our intranasal administration, an easy form of self-administration, may be a more acceptable method compared with subcutaneous injections. In contrast, this drug may reduce adherence because of the need for administration with each meal compared with once-daily or once-weekly administration. Compared with exenatide and liraglutide (2), intranasally administered GLP-1 showed low adverse events, especially nausea and vomiting; however, the low bioavailability can translate to a higher cost. Intranasally administered GLP-1 in combination with dipeptidyl peptidase-4 inhibitors might reduce GLP-1 amount. Long-term treatment with this new nasal GLP-1 should be evaluated in larger trials in order to determine its safety, efficacy, and acceptability as a novel treatment for type 2 diabetes.
